This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Take-Two (TTWO) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Take-Two's (TTWO) fiscal second-quarter performance is expected to have been dented by rising operating expenses despite portfolio strength.
What Awaits Warner Bros. Discovery (WBD) in Q3 Earnings?
by Zacks Equity Research
Warner Bros. Discovery's (WBD) third-quarter results are likely to reflect slow advertising revenues and subscriber growth in viewership amid cost-cutting measures.
Disney (DIS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Disney's (DIS) fiscal fourth-quarter results are expected to reflect declining Disney+ subscriber growth rate amid stiff competition.
Are Medical Stocks Lagging Arcellx (ACLX) This Year?
by Zacks Equity Research
Here is how Arcellx, Inc. (ACLX) and Ardelyx (ARDX) have performed compared to their sector so far this year.
Is Arcellx (ACLX) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Arcellx, Inc. (ACLX) and BellRing Brands (BRBR) have performed compared to their sector so far this year.
Wall Street Analysts Believe Arcellx, Inc. (ACLX) Could Rally 35.56%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 35.6% in Arcellx, Inc. (ACLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
5 Biotech Stocks to Buy as New Drug Approvals Drive Industry Prospects
by Ekta Bagri
New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position EXEL, DVAX, ACLX, ANIP and VNDA well amid volatility.
Gilead's (GILD) Leukemia Study Progress Put on Clinical Hold
by Zacks Equity Research
Gilead (GILD) faces a setback as the FDA puts a partial clinical hold on enrolling new patients in studies evaluating magrolimab for treating AML in the United States.
Does Arcellx, Inc. (ACLX) Have the Potential to Rally 39.12% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 39.1% in Arcellx, Inc. (ACLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies
by Zacks Equity Research
Gilead (GILD) enters into a deal with Tentarix Biotherapeutics to discover and develop novel therapies for cancer and inflammation.
Gilead (GILD) Ends Myelodysplastic Syndromes Study on Magrolimab
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) discontinues phase III ENHANCE study, evaluating the potential of magrolimab as a treatment for higher-risk myelodysplastic syndromes, due to futility based on a planned analysis.
Biotech Stock Roundup: DICE Gains on LLY Buyout, MRSN Down on Update & More
by Zacks Equity Research
Acquisition and regulatory updates from DICE and GSK plc (GSK ) are in focus in the biotech sector.
Arcellx (RCLX) Down on Hold for Lead Program CART-ddBCMA
by Zacks Equity Research
Arcellx's (ACLX) study on lead program CART-ddBCMA for treating adult patients with relapsed or refractory multiple myeloma has been put on hold by the FDA. The company's shares decline on the same.
Arcellx, Inc. (ACLX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arcellx, Inc. (ACLX) delivered earnings and revenue surprises of -123.02% and 86.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights Arcellx, Harrow Health, PROG, Chipotle Mexican Grill and Meta
by Zacks Equity Research
Arcellx, Harrow Health, PROG, Chipotle Mexican Grill and Meta have been highlighted in this Screen of The Week article.
5 Stocks With Recent Price Strength That Still Have Upside
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are META, CMG, ACLX, HROW and PRG.
Arcellx, Inc. (ACLX) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Arcellx, Inc. (ACLX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Arcellx, Inc. (ACLX) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Arcellx, Inc. (ACLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Momentum Stocks to Buy for April 21st
by Zacks Equity Research
ANVS, ACLX and WOR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 21, 2023.
New Strong Buy Stocks for April 21st
by Zacks Equity Research
WOR, RYI, ANVS, ACLX and SIEGY have been added to the Zacks Rank #1 (Strong Buy) List on April 21, 2023.
New Strong Buy Stocks for April 17th
by Zacks Equity Research
IOT, PNTG, ACLX, ELUXY and AB have been added to the Zacks Rank #1 (Strong Buy) List on April 17, 2023.
Best Momentum Stocks to Buy for April 11th
by Zacks Equity Research
ACLX, MT and X made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 11, 2023.
New Strong Buy Stocks for April 11th
by Zacks Equity Research
AGESY, ACLX, MT, X and GBX have been added to the Zacks Rank #1 (Strong Buy) List on April 11, 2023.
Wall Street Analysts Predict a 29.58% Upside in Arcellx, Inc. (ACLX): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 29.6% in Arcellx, Inc. (ACLX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Earnings Estimates Moving Higher for Arcellx, Inc. (ACLX): Time to Buy?
by Zacks Equity Research
Arcellx, Inc. (ACLX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.